Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1/2 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

cabiralizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Synovitis, Pigmented Villonodular × Clear all
NCT03069469 2025-12-18

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Deciphera Pharmaceuticals, LLC

Phase 1/2 Active not recruiting
120 enrolled

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02471716 2021-08-31

FPA008-002

Five Prime Therapeutics, Inc.

Phase 1/2 Completed
66 enrolled 20 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡